임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
34건 표시
- 1상모집 중단 (진행 중)· Multiple SclerosisA Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
리드: 로슈
- 1상모집 중단 (진행 중)· Type 2 Diabetes MellitusA Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity
리드: 로슈
- 1상모집 중단 (진행 중)· Cancer-NeoplasmsA Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
리드: 로슈
- 1상모집 중단 (진행 중)· Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedP-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
협력: 로슈
- 1상모집 중단 (진행 중)· Mantle Cell LymphomaA Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
협력: 로슈
- 1상모집 중단 (진행 중)· Systemic Lupus ErythematosusA First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
리드: 로슈
- 1상모집 중단 (진행 중)· PIK3CA-Mutated CancersA Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
리드: 로슈
- 1상모집 중단 (진행 중)· Large B-cell LymphomaMosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
협력: 로슈
- 1상모집 중단 (진행 중)· B Cell LymphomaMosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
협력: 로슈
- 1상모집 중단 (진행 중)· Diabetic Macular EdemaA Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
리드: 로슈
- 1상모집 중단 (진행 중)· Acute Myeloid LeukemiaEntrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
협력: 로슈
- 1상모집 중단 (진행 중)· Locally Advanced Pancreatic AdenocarcinomaCalaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
협력: 로슈
- 1상모집 중단 (진행 중)· Multiple MyelomaP-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
협력: 로슈
- 1상모집 중단 (진행 중)· Multiple MyelomaA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 로슈
- 1상모집 중단 (진행 중)· Recurrent B-Cell Non-Hodgkin LymphomaAn Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
협력: 로슈
- 1상모집 중단 (진행 중)· Pancreatic CancerStudy of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
협력: 로슈
- 1상모집 중단 (진행 중)· Breast CancerAKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
협력: 로슈
- 1상모집 중단 (진행 중)· Acute Myeloid LeukemiaVenetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
협력: 애브비, 로슈
- 1상모집 중단 (진행 중)· Solid TumorsA Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
리드: 로슈
- 1상모집 중단 (진행 중)· B-Cell Lymphoma, UnspecifiedObinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
협력: 로슈
- 1상모집 중단 (진행 중)· Myelodysplastic Syndromes (MDS)A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
리드: 애브비 · 협력: 로슈
- 1상모집 중단 (진행 중)· MelanomaXL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
협력: 로슈
- 1상모집 중단 (진행 중)· Chronic Lymphocytic LeukemiaA Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
협력: 로슈
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.